Dr. Thomas McGlashan (born 1942) is an American professor of psychiatry at Yale University, well known for his academic contributions to the study of schizophrenia and other mental illnesses.

Professional career

He obtained his medical qualification from the University of Pennsylvania in 1967, and was a staff member in Chestnut Lodge, where according to the New York Times, May 23, 2006, McGlashan "strived for years to master psychoanalysis, only to reject it (for psychosis) after demonstrating, in a landmark 1984 study, that the treatment did not help much at all in people ... with schizophrenia.".[1] These long term follow up and reported outcomes for patients with schizophrenia are known as the Chestnut Lodge studies.[2]

In the 1990s he embarked upon work focused on interventions early in the course of schizophrenia, and became an early advocate and researcher in early detection and intervention for psychosis,[3] including being a key participant in the Norway early detection studies (TIPS) [4] and PRIME studies on early treatment of those at risk of schizophrenia [5] The study reported that the drug Olanzapine had a "trend significant" effect in preventing conversion to psychosis and that further, larger studies are warranted.[6]

Professor Thomas McGlashan is the current recipient of the Richard Wyatt Award,[7] of the International Early Psychosis Association, and of the Psychiatric Research Award of the American Psychiatric Association for his contributions to the field of early detection and intervention in psychosis.

Books

Co-authored:

References

  1. ^ Carey, Benedict (2006-05-23). "A Career That Has Mirrored Psychiatry's Twisting Path". The New York Times. Retrieved 2008-01-18.
  2. ^ McGlashan TH (June 1984). "The Chestnut Lodge follow-up study. I. Follow-up methodology and study sample". Arch. Gen. Psychiatry. 41 (6): 573–85. doi:10.1001/archpsyc.1984.01790170047006. PMID 6428370.
  3. ^ McGlashan TH (1996). "Early detection and intervention in schizophrenia: editor's introduction". Schizophr Bull. 22 (2): 197–9. doi:10.1093/schbul/22.2.197. PMID 8782281.
  4. ^ Johannessen JO, Larsen TK, Joa I, et al. (August 2005). "Pathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study". Br J Psychiatry Suppl. 48 (48): s24–8. doi:10.1192/bjp.187.48.s24. PMID 16055803.
  5. ^ McGlashan TH, Zipursky RB, Perkins D, et al. (May 2003). "The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design". Schizophr. Res. 61 (1): 7–18. doi:10.1016/S0920-9964(02)00439-5. PMID 12648731. S2CID 1118339.
  6. ^ McGlashan TH, Zipursky RB, Perkins D, et al. (May 2006). "Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis". Am J Psychiatry. 163 (5): 790–9. doi:10.1176/appi.ajp.163.5.790. PMID 16648318.
  7. ^ "The Richard J. Wyatt Award". Archived from the original on 2009-10-30. Retrieved 2010-06-23.


Categories